The potent TGF-β antagonist Norrin as a new drug for the treatment of fibrotic diseases and cancer
Human Norrin protein has been originally identified in the art as being a crucial factor in the development of Norrie disease and is thought to be primarily involved in the Wnt signaling pathway. In the present invention, Norrin is
being identified for the first time as a potent TGF-β antagonist/inhibitor. Furthermore, it has surprisingly been found herein that Norrin can be used in the treatment of diseases associated with an increased TGF-β activity level, such as fibrotic diseases and proliferative diseases, resp. cancer.
Further Information: PDF
Bayerische Patentallianz GmbH
Phone: +49 89 5480177-0
Contact
Peer Biskup
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Innovative 3D printed scaffolds offer new hope for bone healing
Researchers at the Institute for Bioengineering of Catalonia have developed novel 3D printed PLA-CaP scaffolds that promote blood vessel formation, ensuring better healing and regeneration of bone tissue. Bone is…
The surprising role of gut infection in Alzheimer’s disease
ASU- and Banner Alzheimer’s Institute-led study implicates link between a common virus and the disease, which travels from the gut to the brain and may be a target for antiviral…
Molecular gardening: New enzymes discovered for protein modification pruning
How deubiquitinases USP53 and USP54 cleave long polyubiquitin chains and how the former is linked to liver disease in children. Deubiquitinases (DUBs) are enzymes used by cells to trim protein…